Recent advances in complement-targeted therapies—including inhibitors of C3, C5, factor B, and MASP-2—are entering glomerular disease trials, with early evidence of efficacy in proteinuria reduction and slowing of glomerular injury. The gene discussed is C5; the disease is glomerular disorder.